

Cancer immunology and therapy

Shirley Parker*

Department of Molecular Cancer, Center for Cancer Research, Cleveland Clinic, USA

Accepted on April 20, 2020

On behalf of the Board of the Journal of Cancer Immunology and Therapy (JCIT) and my co-editors I am proud to introduce you to the first fully open access peer-reviewed online journal in cancer. The journal started publishing in 2018 and has since then published several high quality papers and reviews [1-6]. Journal of Cancer Immunology and Therapy (JCIT) is a peer-reviewed, open access journal that reflects articles on all types of tumor immunology. Though the journal started recently it has completed 2 volumes successfully, volume 1 with 10 articles [1,2] and volume 2 with 13 articles [3-6] and now it is in 3rd volume. This is the result of the work of many people committed to the creation and development of a journal that focuses on standards relevant to the cancer immunology and therapy. Our goal is to provide scholars worldwide with comparative papers on recent developments and research work on cancer on the international level.

It delivers timely interpretations of key scientific developments in Cancer Immunology and its related areas of study. Known personalities with expertise and published studies in a specific field are invited to write reviews and editorials in our journal. Un-invited reviews will also be accepted if written by experts with publications in the field. Manuscripts submitted to the journal will be accepted on the understanding that the author has not previously submitted the paper to another journal or had the material published elsewhere. Manuscripts are rejected if it shows high percentage of plagiarism.

I would like to extend my appreciation to members of the editorial board, who do a substantial amount of work reviewing manuscripts submitted to the journal. In addition to editorial board members, I also rely on ad hoc reviewers to ensure the most appropriate level of expertise for every manuscript submitted to the journal for peer review.

In 2020 journal aims to serve as a forum for new concepts and advances in basic Cancer Discovery, Cancer Epidemiology, Biomarkers & Prevention, Cancer Immunology Research, Cancer Surgery, Advances in Cancer Prevention, Breast Cancer, Cancer Biology, Cancer Treatment, Cancer Management and Research, Integrative Cancer Therapies, Clinical cancer immunology and therapy.

Our editorial policy is governed by independent quality control. It is guaranteed by the Editorial Board. We are proud to have such eminent scholars in our Editorial board which is composed of professors from world. In conclusion, I would like to thank all prominent members of our Editorial Council for

joining us in this new fascinating and promising academic journal and also the reviewers for their constant support and dedication for expert review process. We are looking to expand our panel of reviewers and editorial board from across the various sub specialties in cancer.

I am happy to announce that the journal also now uses social media like facebook, twitter, linkedin, etc. All the articles published in our journal are posted in social media so that it may help readers and researchers globally.

We look forward to work with all of you as we continue to make Journal of Medical Physics and Applied Sciences a success and we welcome your submissions, as well as feedback as authors, readers, and reviewers of the journal.

References

1. Mohindra N. Current state of immunotherapy: chipping away at the tip of the iceberg. *J Cancer Immunol Ther* 2018; 1(1): 1-2.
2. Yubin Z, Qun Z, Herbert S. Recent advances in exosome-based cancer immunotherapy. *J Cancer Immunol Ther* 2018; 1(1): 9-16.
3. Deshpande HA, Pathak R, Riaz F. Advanced and metastatic soft tissue sarcoma, a review of aajcc 8th edition staging and the use of olaratumab. *J Cancer Immunol Ther* 2018; 1(1): 17-23.
4. Venyo AKG. Irreversible electroporation of renal tumours: A review and an update. *J Cancer Immunol Ther* 2019; 2(1): 35-41.
5. Bajaj A. Sweat gland or hair follicle? - Eccrine spiradenoma. *J Cancer Immunol Ther* 2019; 2(1): 31-34.
6. Venyo AKG. Primary leiomyosarcoma of the adrenal gland: A review and update of literature. *J Cancer Immunol Ther* 2019; 2(1): 7-18

*Correspondance to

Shirley Parker
Department of Molecular Cancer
Center for Cancer Research
Cleveland Clinic
USA
E-mail: pshirley11@gmail.com